Cancer therapy-related cardiovascular (CV) disease is an increasing cause of morbidity and mortality among cancer survivors. Current guidelines recommend CV risk prediction tools such as SCORE2; however, these do not account for cancer-specific factors or cardiac biomarkers. Whether incorporating cardio-oncology...
M. Gynnild, H. Dalen, E. Holte et al.· European Heart Journal· 0 citations
Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of recurrent events. Over recent decades, guidelines have intensified secondary prevention strategies targeting risk factors, including low-density lipoprotein-cholesterol (LDL-c), systolic blood pressure (SBP), smoking cess...
E. Wempe, Y. van der Schouw, F. Martens et al.· European Heart Journal· 0 citations
Higher levels of Lp(a) consistently increased the risk of subsequent cardiovascular outcomes, specifically myocardial infarction and coronary or other vascular interventions, across all locations of established ASCVD.
J. Ebbers, E. Haug, M. Gynnild et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.